Immunogenicity during 6 months after SARS-CoV-2 infection is significantly different depending on previous COVID-19 vaccine regimens and a booster dose received.

Publication date: Sep 17, 2024

Data on immunogenicity induced by SARS-CoV-2 infection and its sustainability are essential to inform COVID-19 vaccine schedule. A prospective cohort study was conducted among adults at-risk for COVID-19 during the Omicron variant-dominant epidemic. All were followed up for anti-spike RBD levels on days 0, 14, 90 and 180 after enrollment. Of the 871 individuals included, 264 (30. 3 %) had COVID-19. Those with COVID-19 had significantly lower baseline geometric mean level of anti-spike RBD than those without COVID-19 (326 vs. 989; P

Concepts	Keywords
Epidemic	Adult
Months	Aged
Sustainability	Antibodies, Neutralizing
Vaccine	Antibodies, Neutralizing
	Antibodies, Viral
	Antibodies, Viral
	Booster dose
	COVID-19
	COVID-19
	COVID-19 Vaccines
	COVID-19 Vaccines
	Female
	Humans
	Immunization Schedule
	Immunization, Secondary
	Immunogenicity
	Immunogenicity, Vaccine
	Male
	Middle Aged
	Prospective Studies
	SARS-CoV-2
	SARS-CoV-2
	Spike Glycoprotein, Coronavirus
	Spike Glycoprotein, Coronavirus
	spike protein, SARS-CoV-2
	Vaccine regimen

Semantics

Type	Source	Name
disease	MESH	SARS-CoV-2 infection
pathway	REACTOME	SARS-CoV-2 Infection

Original Article

(Visited 3 times, 1 visits today)